<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704520</url>
  </required_header>
  <id_info>
    <org_study_id>CCR4326</org_study_id>
    <nct_id>NCT02704520</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Tumour Regression Grade as Biomarker for Stratified Management of Rectal Cancer Patients</brief_title>
  <acronym>TRIGGER</acronym>
  <official_title>Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Imaging Biomarker to Stratify Management of Good and Poor Responders to Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates a novel imaging method called magnetic resonance tumour regression grade
      (mrTRG) to assess how well a tumour has responded to chemoradiotherapy in patients with
      rectal cancer. The TRIGGER Trial aims to evaluate mrTRG as a tool for stratifying the
      management of patients according to their response to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately half of patients diagnosed with rectal cancer are offered chemotherapy and
      radiotherapy treatment (CRT) before surgery. There is great variability in how each tumour
      responds to CRT. Approximately 30% of tumours completely respond and no cancer cells can be
      found in the cancer specimen removed at surgery. Other tumours do not respond at all or
      occasionally continue to grow during treatment.

      In many hospitals patients receive an MRI scan before and after CRT treatment. Emerging
      evidence suggests that by viewing the MRI scans in a smarter way by assessing 'mrTRG' (MR
      Tumour Regression Grade) it is possible to assess how the tumour has responded to treatment.
      The TRIGGER Trial aims to evaluate mrTRG as a tool for stratifying patients according to
      their response to treatment.

      Patients will be randomised (1:2 ratio) to a control and intervention arm. Patients in the
      control arm will receive best current practice of surgery at 6-8 weeks after CRT and then a
      standard course of chemotherapy. Patients in the intervention arm will receive a treatment
      plan according to their response to CRT, assessed using the mrTRG. Patients who have a good
      response to CRT will defer surgery until the cancer stops reducing in size or avoid surgery
      altogether if the cancer cannot be detected with repeat scans and assessments. Patients who
      have a poor response to CRT will have additional pre-operative chemotherapy. The
      investigators will be able to see if this reduces the size of the tumour further, before a
      decision is made about proceeding to surgery, and if this lowers the risk of the tumour
      spreading.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient recruitment rate</measure>
    <time_frame>During last 4 months of recruitment</time_frame>
    <description>Total number of patients randomised per month during the last 4 months of recruitment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pathology circumferential resection margin (pCRM) involvement rate</measure>
    <time_frame>Control arm: at 12 weeks. Intervention arm - poor response subgroup: 6 months. Intervention arm - good response subgroup: a median of 2 years.</time_frame>
    <description>Overall pCRM involvement rate between the control and intervention arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug toxicity</measure>
    <time_frame>Up to 1 year.</time_frame>
    <description>Toxicity will be graded using Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade 3-5 adverse events will be compared between the control and intervention arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
    <time_frame>30 days and 12-months</time_frame>
    <description>Surgical morbidity reported according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of surgery</measure>
    <time_frame>Time of surgery</time_frame>
    <description>Quality of surgery determined using the mesorectal grading system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strength of agreement of reported mrTRG between site and central radiologists</measure>
    <time_frame>At baseline and 5 years.</time_frame>
    <description>Agreement (kappa) between site and central radiologists for reported mrTRG for MRI scans performed at baseline, post-CRT and during surveillance schedule.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in the control arm will undergo surgery and then receive a course of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil) and follow-up assessments as standard i.e. standard clinical practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the intervention arm will be split into one of two groups according to their response to chemoradiotherapy. Patients who show a good response (mrTRG I&amp;II) will be offered deferral of surgery and receive the standard course of chemotherapy. Patients who show a poor response (mrTRG III-V) will receive 12 weeks of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil), undergo repeat restaging, and then continue to surgery or defer surgery. Depending on chemotherapy regimen received patients may then receive a further 12 weeks of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Coated tablet. Systemic chemotherapy</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>CAPOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Concentrate for Solution for Infusion. Systemic chemotherapy</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>CAPOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>Infusion. Systemic chemotherapy</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>FOLFOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>Solution for infusion.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>calcium folinate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a biopsy-confirmed adenocarcinoma 0-15cm from the anal verge (on MRI or rigid
             sigmoidoscopy).

          2. Have locally Advanced Rectal Carcinoma diagnosed by MRI (mrCRM unsafe or â‰¥mrT3c [&gt;5mm
             beyond muscularis propria] or mrEMVI positive disease)

          3. Be deemed to require chemoradiotherapy.

          4. Scheduled to receive 45Gy - 55Gy long course radiotherapy.

          5. Have provided written informed consent to participate in the study.

          6. Be aged 18 years or over.

        Exclusion Criteria:

          1. Have metastatic disease (including resectable liver metastases).

          2. Are contraindicated for MRI e.g. non-MR compatible hip prosthesis, cardiac pacemaker.

          3. Are scheduled to receive less than 45Gy or more than 55Gy long course radiotherapy.

          4. Are contraindicated for chemoradiotherapy (CRT)

          5. Hypersensitivity or contraindication to the drug(s) associated with the planned choice
             of systemic chemotherapy (CAPOX, FOLFOX or single agent 5-FU or capecitabine) as
             stated in the SmPC for each of the drugs.

          6. Are receiving or planned to receive treatment outside of that stipulated by the
             protocol, such as an alternative cytotoxic or investigational drug.

          7. Are pregnant, breastfeeding or unable / unwilling to comply with pregnancy prevention
             guidelines.

          8. Any other malignant disease within the preceding 5 years with the exception of non-
             melanomatous skin cancer, carcinoma in situ and early stage disease with &lt;5%
             recurrence risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Frost</last_name>
    <phone>44 (0)208 915 6067</phone>
    <email>michelle.frost@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ceri Evans</last_name>
    <phone>44 (0) 208 642 6011</phone>
    <phone_ext>4280</phone_ext>
    <email>ceri.evans@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hampshire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Topping</last_name>
      <phone>01256 313918</phone>
      <email>megan.topping@hhft.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Palmer</last_name>
      <phone>01256 313918</phone>
      <email>caroline.palmer@hhft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Brendan Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mit Dattani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salisbury NHS Foundation Trust</name>
      <address>
        <city>Salisbury</city>
        <state>Wiltshire</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Strong-Sheldrake</last_name>
      <phone>01722 336262</phone>
      <phone_ext>4191</phone_ext>
      <email>sophia.strong-sheldrake@salisbury.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Julie Attlee</last_name>
      <phone>01722 336262</phone>
      <phone_ext>4191</phone_ext>
      <email>julie.attlee@salisbury.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Graham Branagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alaaeldin Shablak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Hollister</last_name>
      <phone>+44 1173426742</phone>
      <email>robert.hollister@uhbristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stephen Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colchester General Hospital</name>
      <address>
        <city>Colchester</city>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Thorogood</last_name>
      <phone>+44 1206 745 355</phone>
      <email>lucy.thorogood@colchesterhospital.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Celine Driscoll</last_name>
      <phone>+44 1206 745 355</phone>
      <email>celine.driscoll@colchesterhospital.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Sizer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Lanarkshire - Hairmyres Hospital</name>
      <address>
        <city>East Kilbride</city>
        <zip>G75 8RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Devlin</last_name>
      <phone>+44 1355 585329</phone>
      <email>louise.devlin@lanarkshire.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Angela Scullion</last_name>
      <phone>+44 1355 585 329</phone>
      <email>angela.scullion@lanarkshire.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Cindy Chew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diana Princess of Wales Hospital</name>
      <address>
        <city>Grimsby</city>
        <zip>DN33 2BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Hatton</last_name>
      <phone>+44 3033 303555</phone>
      <email>jonathan.hatton@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Rajarshi Roy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Wilson</last_name>
      <phone>+44 1642 383 277</phone>
      <email>Helen.Wilson2@nth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lynda Poole</last_name>
      <phone>+44 1642 383 277</phone>
      <email>Lynda.Poole@nth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>David Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Frost</last_name>
      <phone>44 (0) 208 915 6067</phone>
      <email>michelle.frost@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ceri Evans</last_name>
      <phone>44 (0)208 642 6011</phone>
      <phone_ext>4280</phone_ext>
      <email>ceri.evans@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Sheela Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Diagnostic Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

